Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola Lang

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
BMJ (Clinical Research Ed.)|November 11, 2006
Measles outbreak in SurreyPeter M English, Nicola Lang, Anna Raleigh, et al.
Optics Express|May 4, 2026
Confocal photoluminescence mapping of diamond photonic crystal cavity modes for the silicon vacancy centerLin Jin, Mark Ulanov, Stefan Dietel, et al.
AJR. American Journal of Roentgenology|March 22, 2008
Whole-body MRI versus whole-body MDCT for staging of multiple myelomaAndrea Baur-Melnyk, Sonja Buhmann, Christoph Becker, et al.
The Journal of Infection|November 7, 2020
Seropositivity and risk factors for SARS-CoV-2 infection in staff working in care homes during the COVID-19 pandemicThomas A J Rowland, Heather Whitaker, Anna Jeffery-Smith, et al.
British Journal of Haematology|August 6, 2003
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myelomaMartin H Kropff, Nicola Lang, Guido Bisping, et al.
The Journal of Infection|September 19, 2020
Regular mass screening for SARS-CoV-2 infection in care homes already affected by COVID-19 outbreaks: Implications of false positive test resultsShamez N Ladhani, J Yimmy Chow, Sara Atkin, et al.
British Journal of Haematology|July 7, 2007
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaMartin Kropff, Guido Bisping, Elke Schuck, et al.
Blood|November 10, 2005
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroupsGuido Bisping, Martin Kropff, Doris Wenning, et al.
Haematologica|September 24, 2016
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trialChristian Straka, Peter Liebisch, Hans Salwender, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
BMJ (Clinical Research Ed.)|November 11, 2006
Measles outbreak in SurreyPeter M English, Nicola Lang, Anna Raleigh, et al.
Optics Express|May 4, 2026
Confocal photoluminescence mapping of diamond photonic crystal cavity modes for the silicon vacancy centerLin Jin, Mark Ulanov, Stefan Dietel, et al.
AJR. American Journal of Roentgenology|March 22, 2008
Whole-body MRI versus whole-body MDCT for staging of multiple myelomaAndrea Baur-Melnyk, Sonja Buhmann, Christoph Becker, et al.
The Journal of Infection|November 7, 2020
Seropositivity and risk factors for SARS-CoV-2 infection in staff working in care homes during the COVID-19 pandemicThomas A J Rowland, Heather Whitaker, Anna Jeffery-Smith, et al.
British Journal of Haematology|August 6, 2003
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myelomaMartin H Kropff, Nicola Lang, Guido Bisping, et al.
The Journal of Infection|September 19, 2020
Regular mass screening for SARS-CoV-2 infection in care homes already affected by COVID-19 outbreaks: Implications of false positive test resultsShamez N Ladhani, J Yimmy Chow, Sara Atkin, et al.
British Journal of Haematology|July 7, 2007
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaMartin Kropff, Guido Bisping, Elke Schuck, et al.
Blood|November 10, 2005
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroupsGuido Bisping, Martin Kropff, Doris Wenning, et al.
Haematologica|September 24, 2016
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trialChristian Straka, Peter Liebisch, Hans Salwender, et al.
Pageof 1